Last reviewed · How we verify
GSK4527226
At a glance
| Generic name | GSK4527226 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Open-label Extension Study in Participants With Early Alzheimer's Disease (PHASE2)
- Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |